Low-dose Colchicine for CABG Graft Failure Prevention

Summary

This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.

Timeline

Start

2026-09-01

Primary completion

2028-09-01

Completion

2029-09-01

Drugs

Indications